HER2+ Breast Cancer

The FDA’s Oncologic Drugs Advisory Committee will no longer be meeting to review a Biologics License Application for margetuximab for the treatment of patients with HER2-positive breast cancer.

Fam-trastuzumab deruxtecan-nxki (Enhertu) demonstrated continued benefit in patients with HER2-positive breast cancer who had stable, treated brain metastases at baseline.

Yeon Hee Park, MD, discusses the utility and benefit of fam-trastuzumab deruxtecan-nxki in HER2-positive metastatic breast cancer, specifically in patients with central nervous system metastases.

Therapeutic options for pretreated HER2-positive breast cancer now include tucatinib (Tukysa) as part of a triplet regimen with a tolerable safety profile that promises improved quality of life.

The degree to which nature and nurture affect disease has long been debated in medicine, and it is an issue that esteemed breast cancer researcher and medical oncologist Joyce A. O’Shaughnessy, MD, has been working to unravel for her patients throughout a career that spans more than 30 years.

Tucatinib has been approved in Switzerland for use in combination with trastuzumab and capecitabine for patients with previously treated metastatic HER2-positive breast cancer.

Erika P. Hamilton, MD, discusses the evolution of treatment in HER2-positive breast cancer.

Trastuzumab emtansine has been approved in the UK for the adjuvant treatment of patients with HER2-positive early breast cancer.